Xilio Therapeutics (NASDAQ:XLO) Announces Earnings Results

Xilio Therapeutics (NASDAQ:XLO) released its quarterly earnings data on Monday. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.68) by $2.49, FiscalAI reports. The firm had revenue of $13.69 million during the quarter, compared to analyst estimates of $10.90 million. Xilio Therapeutics had a negative return on equity of 679.66% and a negative net margin of 183.90%.

Xilio Therapeutics Stock Performance

Shares of NASDAQ:XLO opened at $7.86 on Monday. The business has a fifty day moving average of $8.05 and a 200-day moving average of $9.62. Xilio Therapeutics has a twelve month low of $6.47 and a twelve month high of $16.52. The firm has a market cap of $41.27 million, a PE ratio of -0.86 and a beta of -0.05.

Institutional Investors Weigh In On Xilio Therapeutics

A number of hedge funds have recently added to or reduced their stakes in XLO. Squarepoint Ops LLC lifted its holdings in Xilio Therapeutics by 39.6% during the 3rd quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after buying an additional 93,338 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Xilio Therapeutics by 68.3% in the 4th quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock valued at $220,000 after acquiring an additional 139,716 shares during the last quarter. Jane Street Group LLC acquired a new stake in Xilio Therapeutics in the fourth quarter worth $27,000. State Street Corp raised its stake in Xilio Therapeutics by 13.7% during the 4th quarter. State Street Corp now owns 186,390 shares of the company’s stock worth $119,000 after buying an additional 22,500 shares during the period. Finally, Velan Capital Investment Management LP acquired a new stake in shares of Xilio Therapeutics during the fourth quarter worth about $109,000. Institutional investors own 54.29% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xilio Therapeutics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $28.00.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.